GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)
- Conditions
- DiphtheriaTetanusHaemophilus Influenzae Type bPoliomyelitisAcellular Pertussis
- Interventions
- Biological: Infanrix™-IPV/Hib
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00964028
- Locations
- 🇨🇳
GSK Investigational Site, Wuzhou, Guangxi, China
Phase I Study of GSK233705 in Healthy Japanese Male Subjects
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00964405
- Locations
- 🇯🇵
GSK Investigational Site, Fukuoka, Japan
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
- Conditions
- Migraine Disorders
- Interventions
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 178
- Registration Number
- NCT00963937
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Phase I Study of GW642444M in Healthy Japanese Male Subjects
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GW642444Drug: Placebo
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT00964249
- Locations
- 🇯🇵
GSK Investigational Site, Fukuoka, Japan
Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation
- Conditions
- Drug Interactions
- Interventions
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 87
- Registration Number
- NCT00964106
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00964340
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine GSK134612Biological: Meningitec™
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 342
- Registration Number
- NCT00955682
- Locations
- 🇫🇮
GSK Investigational Site, Vantaa, Finland
GSK2190915 Safety and Pharmacokinetic Study in Healthy Japanese Subjects
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00955383
- Locations
- 🇩🇪
GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany
A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 64
- Registration Number
- NCT00955773
- Locations
- 🇫🇷
GSK Investigational Site, Paris Cedex 20, France
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
- Conditions
- Influenza
- Interventions
- Biological: GSK investigational vaccine GSK2340272ABiological: GSK investigational vaccine GSK2340269A
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2018-11-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 130
- Registration Number
- NCT00951041
- Locations
- 🇩🇪
GSK Investigational Site, Dresden, Sachsen, Germany